Brief: Indaptus Therapeutics Doses First Subject In Its Ongoing Phase 1 Open Label Clinical Trial Of Decoy20 In Patients With Advanced Solid Tumors

Indaptus Therapeutics

07/03/2023 13:29

March 7 (Reuters) - Indaptus Therapeutics Inc  INDP.O :
    * INDAPTUS THERAPEUTICS DOSES FIRST SUBJECT IN ITS ONGOING
PHASE 1
OPEN LABEL CLINICAL TRIAL OF DECOY20 IN PATIENTS WITH ADVANCED
SOLID TUMORS

Source text for Eikon:  ID:nGNX2Ht0jt 
Further company coverage:  INDP.O 

 ((Reuters.Briefs@thomsonreuters.com;))